Identification of RAI3 as a therapeutic target for breast cancer
Authors:
Open Access
- 1 March 2005
- journal article
- research article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 12 (1) , 65-73
Abstract
We have been investigating gene-expression profiles in estrogen receptor (ER)-negative breast cancers to identify molecules involved in breast carcinogenesis and to select genes or gene products that might be useful as diagnostic markers or targets for new molecular therapies. Here we report evidence that the gene encoding retinoic acid-induced protein 3 (RAI3) is a potential molecular target for treatment of breast cancers. Using quantitative reverse transcription-PCR (RT-PCR), we documented increased expression of RAI3 in 19 of 25 primary breast cancers and in 6 of 11 breast-cancer cell lines examined, by comparison with normal mammary-gland tissue. Treatment of human embryonic kidney (HEK293) cells with siRNA against RAI3 suppressed expression of RAI3 and also suppressed cell growth. Transfection of siRNA into breast-cancer cell lines MCF7 and T47D also suppressed RAI3 mRNA and growth of the cancer cells. Because our data imply that up-regulation of RAI3 function is a frequent feature of breast carcinogenesis, we suggest that selective suppression of signal from RAI3 might hold promise for development of a new strategy for treating breast cancers.Keywords
This publication has 18 references indexed in Scilit:
- Treatment of HER-2/ neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell FractionClinical Cancer Research, 2004
- Expression profiling to predict postoperative prognosis for estrogen receptor‐negative breast cancers by analysis of 25,344 genes on a cDNA microarrayCancer Science, 2004
- Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cellsBritish Journal of Cancer, 2004
- Isolation of development and differentiation enhancing factor-like 1 (DDEFL1) as a drug target for hepatocellular carcinomas.International Journal of Oncology, 2004
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Activation of the interferon system by short-interfering RNAsNature Cell Biology, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Initial sequencing and analysis of the human genomeNature, 2001
- Drug Discovery: A Historical PerspectiveScience, 2000
- Molecular Cloning and Characterization of a Novel Retinoic Acid-inducible Gene That Encodes a Putative G Protein-coupled ReceptorJournal of Biological Chemistry, 1998